Zalicus has two unique drug discovery platforms that fuel its product pipeline and enable additional revenue generating collaborations. Our industry leading selective ion channel modulation platform allows us to identify product candidates that harness the potential of the electrophysiology of calcium channel blockers for acute and chronic pain. Our proprietary cell-based combination High Throughput Screening (cHTS) technology evaluates the therapeutic potential of various drug combinations while elucidating new mechanisms to treat diseases.
